The advent of COVID-19 [1] has demarcated time into pre and post COVID-19. A complex condition under the umbrella of neurodevelopmental disorders (NDD), autism spectrum disorder (ASD), is a cause of much public concern. The Centre for Disease Control (CDC) most recent reports estimate that an average of 1:36 children in the U.S. has been identified with ASD [2] an increase from the previously reported rates of 1:54, 1:88, 1:110, and 1:150.